Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction.

Gong J, Cho M, Gupta R, Synold TW, Frankel P, Ruel C, Fakih M, Chung V, Lim D, Chao J.

Oncologist. 2019 Feb 1. pii: theoncologist.2018-0336. doi: 10.1634/theoncologist.2018-0336. [Epub ahead of print]

PMID:
30710067
2.

A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity.

Cristea MC, Frankel P, Synold T, Rivkin S, Lim D, Chung V, Chao J, Wakabayashi M, Paz B, Han E, Lin P, Leong L, Hakim A, Carroll M, Prakash N, Dellinger T, Park M, Morgan RJ.

Cancer Chemother Pharmacol. 2019 Mar;83(3):589-598. doi: 10.1007/s00280-019-03767-9. Epub 2019 Jan 8.

PMID:
30623229
3.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC.

J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27.

PMID:
29584545
4.

Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer.

Chao J, Lin J, Frankel P, Clark AJ, Wiley DT, Garmey E, Fakih M, Lim D, Chung V, Luevanos E, Eliasof S, Davis ME, Yen Y.

J Gastrointest Oncol. 2017 Dec;8(6):962-969. doi: 10.21037/jgo.2017.08.10.

5.

A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy.

Cho M, Gong J, Frankel P, Synold TW, Lim D, Chung V, Chao J, Li D, Chen Y, Sentovich S, Melstrom K, Singh G, Luevanos E, Fakih M.

Oncotarget. 2017 Jul 18;8(45):79750-79760. doi: 10.18632/oncotarget.19336. eCollection 2017 Oct 3.

6.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
7.

Complete response of skull base inverted papilloma to chemotherapy: Case report.

Kuan EC, Frederick JW, Palma Diaz MF, Lim DW, Suh JD.

Allergy Rhinol (Providence). 2017 Jun 1;8(2):105-108. doi: 10.2500/ar.2017.8.0201.

8.

Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer.

Hurria A, Akiba C, Kim J, Mitani D, Loscalzo M, Katheria V, Koczywas M, Pal S, Chung V, Forman S, Nathwani N, Fakih M, Karanes C, Lim D, Popplewell L, Cohen H, Canin B, Cella D, Ferrell B, Goldstein L.

J Oncol Pract. 2016 Dec;12(12):e1025-e1034. Epub 2016 Sep 30.

9.

Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma.

Chung V, Frankel P, Lim D, Yeon C, Leong L, Chao J, Ruel N, Luevanos E, Koehler S, Chung S, Lau SC, Fakih MG.

Oncology. 2016;90(6):307-12. doi: 10.1159/000445297. Epub 2016 Apr 20.

PMID:
27093189
10.

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.

Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R, Chmielowski B, Ribas A, Davis ME, Yen Y.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11449-54. doi: 10.1073/pnas.1411393111. Epub 2014 Jul 21.

11.

p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.

Hardwick NR, Carroll M, Kaltcheva T, Qian D, Lim D, Leong L, Chu P, Kim J, Chao J, Fakih M, Yen Y, Espenschied J, Ellenhorn JD, Diamond DJ, Chung V.

Clin Cancer Res. 2014 Sep 1;20(17):4459-70. doi: 10.1158/1078-0432.CCR-13-3361. Epub 2014 Jul 1. Erratum in: Clin Cancer Res. 2017 Jan 1;23 (1):322.

12.

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.

Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K.

Invest New Drugs. 2014 Feb;32(1):113-22. doi: 10.1007/s10637-013-9956-5. Epub 2013 Apr 9.

13.

Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: a retrospective review.

Lau SC, Chung V, Lim D, Shibata S.

J Oncol Pharm Pract. 2014 Apr;20(2):83-7. doi: 10.1177/1078155212474048. Epub 2013 Jan 24.

PMID:
23353714
14.

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.

Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1391-8.

15.

Antiemesis.

Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):456-85. No abstract available.

PMID:
22491046
16.

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.

Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y.

Cancer Chemother Pharmacol. 2012 Mar;69(3):835-43. doi: 10.1007/s00280-011-1779-5. Epub 2011 Nov 22.

17.

Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.

Luu T, Chow W, Lim D, Koczywas M, Frankel P, Cristea M, Margolin K, Doroshow JH, Somlo G, Gaur S, Yen Y, Morgan RJ.

Anticancer Res. 2010 Jan;30(1):167-74.

PMID:
20150632
18.

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.

Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH.

Cancer Chemother Pharmacol. 2010 Oct;66(5):927-33. doi: 10.1007/s00280-010-1242-z. Epub 2010 Jan 28.

19.

Image-guided Radiotherapy Of Esophageal Cancer By Helical Tomotherapy: Acute Toxicity And Preliminary Clinical Outcome.

Chen YJ, H Kernstine K, Shibata S, Lim D, D Smith D, Tang M, Liu A, D Pezner R, Y C Wong J.

J Thorac Dis. 2009 Dec;1(1):11-6.

20.

Antiemesis. Clinical Practice Guidelines in Oncology.

Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, Nabati L, Nesheiwat C, Rugo HS, Sorscher SM, Stucky-Marshal L, Todaro B, Urba S.

J Natl Compr Canc Netw. 2009 May;7(5):572-95. No abstract available.

PMID:
19460282
21.

Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial.

Jo S, Juhasz A, Zhang K, Ruel C, Loera S, Wilczynski SP, Yen Y, Liu X, Ellenhorn J, Lim D, Paz B, Somlo G, Vora N, Shibata S.

Anticancer Res. 2009 May;29(5):1467-74.

22.

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.

Shibata SI, Doroshow JH, Frankel P, Synold TW, Yen Y, Gandara DR, Lenz HJ, Chow WA, Leong LA, Lim D, Margolin KA, Morgan RJ, Somlo G, Newman EM.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1149-55. doi: 10.1007/s00280-009-0977-x. Epub 2009 Mar 26.

23.

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.

Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G.

Clin Cancer Res. 2008 Nov 1;14(21):7138-42. doi: 10.1158/1078-0432.CCR-08-0122. Erratum in: Clin Cancer Res. 2009 Jan 1;15(1):416.

24.

Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.

Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, Shibata SI, Wagman LD, Marx H, Chu PG, Longmate JA, Lenz HJ, Ramanathan RK, Belani CP, Gandara DR.

Am J Clin Oncol. 2008 Aug;31(4):317-22. doi: 10.1097/COC.0b013e318162f57d. Erratum in: Am J Clin Oncol. 2009 Feb;32(1):98. Wagman, Stephen D [corrected to Wagman, Lawrence D].

PMID:
18845988
25.

Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution.

Chen YJ, Liu A, Han C, Tsai PT, Schultheiss TE, Pezner RD, Vora N, Lim D, Shibata S, Kernstine KH, Wong JY.

Med Dosim. 2007 Fall;32(3):166-71.

PMID:
17707195
26.

Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.

Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, Schwarz RE, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Tetef M, Lin P, Paz B, Koczywas M, Wagman L, Chu D, Frankel P, Stalter S, Doroshow JH.

Clin Cancer Res. 2007 Feb 15;13(4):1232-7.

27.

Antiemesis.

Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, McNulty R, Nabati L, Todaro B, Urba S, Yowell S; National comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2007 Jan;5(1):12-33. No abstract available.

PMID:
17239323
28.

A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.

Shibata S, Chow W, Frankel P, Juhasz A, Leong L, Lim D, Margolin K, Morgan R, Newman E, Somlo G, Yen Y, Synold T, Gandara D, Lenz HJ, Doroshow J.

Cancer Chemother Pharmacol. 2007 Mar;59(4):549-57. Epub 2006 Oct 19.

PMID:
17051371
29.

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.

Margolin KA, Doroshow JH, Frankel P, Chow W, Leong LA, Lim D, McNamara M, Morgan RJ, Shibata S, Somlo G, Twardowski P, Yen Y, Kogut N, Schriber J, Alvarnas J, Stalter S.

Biol Blood Marrow Transplant. 2005 Nov;11(11):903-11.

30.

Senior adult oncology clinical practice guidelines in oncology.

Balducci L, Cohen HJ, Engstrom PF, Ettinger DS, Halter J, Gordon LI, Kiel K, Kneier A, Lim D, Petersdorf SH, Rosenthal R, Silliman R, Vose JM, Walker MJ, Zachariah B; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jul;3(4):572-90. No abstract available.

PMID:
16038647
31.

Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy.

Lim D, Morgan RJ Jr, Akman S, Margolin K, Carr BI, Leong L, Odujinrin O, Doroshow JH.

Invest New Drugs. 2005 Jun;23(3):235-9.

PMID:
15868379
32.

Antiemesis clinical practice guidelines in oncology.

Ettinger DS, Bierman PJ, Bradbury B, Ellis G, Ignoffo RJ, Kirkegaard S, Kloth D, Krauss A, Kris MG, Lim D, Markiewicz MA, McNulty R, Noonan K, Stucky-Marshall L, Todaro B, Urba S, Yowell S; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2004 Sep;2(5):470-90. No abstract available.

PMID:
19780255
33.

Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.

Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ Jr, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH.

Cancer Chemother Pharmacol. 2004 Sep;54(3):241-8. Epub 2004 Jun 2.

PMID:
15173955
34.

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.

Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, Shibata S, Chu P, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas J, Kogut N, Schriber J, Fermin E, Yen Y, Damon L, Doroshow JH.

J Clin Oncol. 2004 May 15;22(10):1839-48.

PMID:
15143076
35.

Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.

Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5896-901.

Supplemental Content

Loading ...
Support Center